Culbertson A N & Co. Inc. Sells 4,865 Shares of Pfizer Inc. $PFE

Culbertson A N & Co. Inc. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 23.1% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 16,177 shares of the biopharmaceutical company’s stock after selling 4,865 shares during the quarter. Culbertson A N & Co. Inc.’s holdings in Pfizer were worth $392,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Pinnacle Wealth Planning Services Inc. boosted its position in Pfizer by 17.4% in the second quarter. Pinnacle Wealth Planning Services Inc. now owns 24,875 shares of the biopharmaceutical company’s stock worth $603,000 after purchasing an additional 3,686 shares during the last quarter. Frank Rimerman Advisors LLC lifted its stake in shares of Pfizer by 9.8% in the 2nd quarter. Frank Rimerman Advisors LLC now owns 154,336 shares of the biopharmaceutical company’s stock worth $3,741,000 after purchasing an additional 13,743 shares during the period. WBI Investments LLC boosted its holdings in shares of Pfizer by 35.6% in the second quarter. WBI Investments LLC now owns 149,419 shares of the biopharmaceutical company’s stock worth $3,622,000 after buying an additional 39,211 shares during the last quarter. Capital Square LLC grew its position in Pfizer by 13.4% during the second quarter. Capital Square LLC now owns 14,311 shares of the biopharmaceutical company’s stock valued at $367,000 after buying an additional 1,693 shares during the period. Finally, LSV Asset Management grew its position in Pfizer by 6.6% during the second quarter. LSV Asset Management now owns 16,149,959 shares of the biopharmaceutical company’s stock valued at $391,475,000 after buying an additional 996,845 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on PFE shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Bank of America lifted their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. UBS Group restated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Citigroup lifted their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.28.

Pfizer Trading Down 0.0%

Shares of PFE stock opened at $25.06 on Tuesday. The stock has a fifty day simple moving average of $24.81 and a two-hundred day simple moving average of $24.45. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The firm has a market capitalization of $142.47 billion, a PE ratio of 13.33, a PEG ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is 100.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.